Boehringer Ingelheim

Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
ERS COPD Research Award 2009 sponsored by Boehringer Ingelheim 21 September 2009
Novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin 02 September 2009
Good first six months in 2009 for Boehringer Ingelheim 30 July 2009
European Commission approves statement on lipid improvement for Viramune® label 07 July 2009
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration 16 June 2009
Outcome of new Mirapexin®/Sifrol® (pramipexole) study 04 May 2009
European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia 26 October 2008
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme 03 October 2008